AstraZeneca CEO Pascal Soriot [via AP]

As­traZeneca's flag­ship Tagris­so helps lung can­cer pa­tients live longer in piv­otal study

As­traZeneca is off to a good start in Au­gust. Af­ter its PARP in­hibitor Lyn­parza scored in a prostate can­cer tri­al ear­li­er this week, the British drug­mak­er on Fri­day dis­closed that its star can­cer drug Tagris­so helped pa­tients with a cer­tain type of lung can­cer live longer in a late-stage study.

The over­all sur­vival da­ta fol­lows pos­i­tive pro­gres­sion-free sur­vival da­ta un­veiled in 2017 from the FLAU­RA Phase III tri­al in­volv­ing pa­tients with metasta­t­ic epi­der­mal growth fac­tor re­cep­tor (EGFR) mu­ta­tion-pos­i­tive non-small cell lung can­cer (NSCLC). As­traZeneca es­ti­mates rough­ly 10-15% of pa­tients in the US and Eu­rope, and 30-40% of pa­tients in Asia have EGFR-mu­tat­ed NSCLC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.